Myriad Genetics Reports Fiscal Second-Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
February 3, 2015 4:08 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $184.4 million versus the consensus estimate of $183.41 million.
Myriad Genetics sees FY2015 EPS of $1.50 - $1.55, versus the consensus of $1.85. Myriad Genetics sees FY2015... More
